Rocket Pharmaceuticals
Open
$3.49
Prev. Close
$3.50
High
$3.50
Low
$3.49
Market Snapshot
$376.61M
-1.7
-2.73
202
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. The company is headquartered in Cranbury, New Jersey and currently employs 202 full-time employees. The company went IPO on 2015-02-18. The firm has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.
emptyResult
Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. The company is headquartered in Cranbury, New Jersey and currently employs 202 full-time employees. The company went IPO on 2015-02-18. The firm has two clinical stage and one pre-clinical stage in vivo adeno-associated viral (AAV) programs in the United States, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardiac disorder that is characterized by a progressive loss of cardiac muscle mass, severe right ventricular dilation, dysplasia, fibrofatty replacement of the myocardium and a high propensity to arrhythmias and sudden death (RP-A601), and BAG3 Dilated Cardiomyopathy (BAG3-DCM), which is the most common form of cardiomyopathy and is characterized by progressive thinning of the walls of the heart resulting in enlarged heart chambers that are unable to pump blood.
Recently from Cashu
Rocket Pharmaceuticals Utilizes FDA Voucher to Fuel Growth in Rare Disease Treatment
Rocket Pharmaceuticals Leverages FDA Voucher for Strategic Growth Rocket Pharmaceuticals, a leader in the development of innovative therapies for rare genetic diseases, is taking a strategic step to e…
Rocket Pharmaceuticals and Avant Technologies: Leading Precision Medicine in Cardiovascular Health
Avant Technologies: Pioneering Precision Medicine in Cardiovascular Health Avant Technologies Inc., a Vancouver-based company, emerges as a significant player in the burgeoning field of precision medi…
Rocket Pharmaceuticals: Pioneering Precision Medicine in Cardiovascular Health and Gene Therapies
Precision Medicine and Cardiovascular Health: A New Era in Therapeutics Rocket Pharmaceuticals operates within a rapidly evolving landscape of precision medicine, a sector that is witnessing unprecede…
Rocket Pharmaceuticals Advances Gene Therapy for Rare Genetic Disorders with Promising Clinical Trials
Rocket Pharmaceuticals Advances Gene Therapy for Rare Diseases Rocket Pharmaceuticals, a leader in the field of gene therapy, continues to make strides in the treatment of rare genetic disorders. The…